(MENAFN- Bangladesh Monitor) Dhaka : Several Hajj agencies in Bangladesh have started receiving applications following Saudi Arabia's recent announcement to accept foreign Umrah pilgrims this year. However, the intended pilgrims' vaccination status has to be approved by Saudi Arabia which on August 24 approved Chinese Sinopharm or Sinovac vaccines.
However, confusion still remains as travellers with Sinopharm vaccines have to receive a booster shot of another vaccine approved by the Middle Eastern country. And Bangladesh is yet to introduce booster doses.
Hajj Agencies Association of Bangladesh said thousands of intended pilgrims have already applied to perform Umrah.
HAAB President Shahadat Hossain Taslim on August 25 said intended pilgrims are expected to fly to Saudi Arabia from September.
Bangladeshi Muslims could not perform Hajj and Umrah in the last two years amid the pandemic.
At present, many intended pilgrims, both vaccinated and unvaccinated, have been enquiring about their eligibility to perform Umrah in Saudi Arabia, said the HAAB President.
In pre-pandemic times, about 2,50,000 Bangladeshis could perform Umrah in a year.
HAAB President urged the government to ensure inoculation of intended pilgrims with vaccines that are approved by Saudi Arabia.
The religious affairs ministry has published a list of 247 agencies that will be allowed to arrange for Umrah from Bangladesh, the ministry's secretary Nurul Islam told a webinar on August 22.
Meanwhile, on August 24 Saudi Arabia approved two more Covid-19 vaccines -- Sinovac and Sinopharm.
However, the Saudi government mentioned those who were fully inoculated with Sinopharm or Sinovac can be accepted into Saudi Arabia, provided they receive a booster shot of a vaccine approved in the Middle Eastern country.
The HAAB president claimed uncertainty still exists over the issue as booster dose has not yet been introduced in Bangladesh.
Earlier, there were four vaccines approved for use in Saudi Arabia: Oxford-AstraZeneca, Pfizer-BioNTech, Johnson and Johnson's Janssen, and Moderna.
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.